Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
Year: 2016
Type: article
Source: Clinical Pharmacokinetics
Authors: Min Zhu, Benjamin Wu, Christian Brandl, Jessica Johnson, Andreas Wolf, Andrew Chow, Sameer Doshi
Institutions: Amgen (United States), Amgen (Germany)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: blinatumomab, bispecific T-cell engagers, CD19, pharmacokinetics, pharmacodynamics, relapsed/refractory B-cell acute lymphoblastic leukemia, non-Hodgkin lymphoma, minimal residual disease, dosing regimen, cytokine production, creatinine clearance, drug interactions, T cell redistribution, B-cell depletion
Open Access status: closed
Funder: Amgen
OpenAlex ID: W2403074774
